Fiera Capital Corp Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

Fiera Capital Corp lessened its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 2.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 127,800 shares of the biopharmaceutical company’s stock after selling 2,822 shares during the period. Fiera Capital Corp owned 0.58% of Madrigal Pharmaceuticals worth $58,617,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in MDGL. Mather Group LLC. purchased a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth $33,000. Global Retirement Partners LLC increased its holdings in shares of Madrigal Pharmaceuticals by 221.7% in the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 51 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Madrigal Pharmaceuticals in the third quarter worth about $34,000. AlphaQuest LLC boosted its stake in Madrigal Pharmaceuticals by 412.5% during the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 66 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Madrigal Pharmaceuticals by 114.3% during the 3rd quarter. GAMMA Investing LLC now owns 90 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 48 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q4 and full‑year Rezdiffra (resmetirom) sales were solid — $321.1M in Q4 and $958.4M for the year, with >36,250 patients on therapy, supporting commercial traction and revenue momentum. GlobeNewswire: Q4 and FY2025 Results
• Positive Sentiment: Company highlights an expanding, industry‑leading MASH pipeline with >10 programs at various stages — supports longer‑term growth potential beyond current drug sales. GlobeNewswire: Pipeline Details
• Positive Sentiment: Strong year‑end liquidity — cash, equivalents and marketable securities totaled ~$988.6M, which gives the company runway to fund commercialization and R&D. GlobeNewswire: Cash Position
• Neutral Sentiment: Investor materials and management commentary are available (conference call, slide deck and transcript) for details on commercialization cadence and pipeline timelines; these may clarify guidance and near‑term expectations. Slide Deck / Call Materials
• Negative Sentiment: Big EPS miss: reported Q4 loss of ($2.57) per share vs. analyst estimate of $0.04 — the wider‑than‑expected loss is the primary catalyst for the sell‑off today. Zacks: Q4 Loss
• Negative Sentiment: Company remains unprofitable (negative return on equity ~41.5% and negative net margin ~39%), and some analysts highlighted the wider loss in market commentary. Seeking Alpha: Market Reaction
• Negative Sentiment: Volume spiked versus average, consistent with heavy selling pressure after the results; combined with the EPS miss this is driving the stock lower. MarketBeat: Trading Snapshot

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, Director Paul A. Friedman sold 24,800 shares of the firm’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $552.18, for a total transaction of $13,694,064.00. Following the transaction, the director directly owned 187,164 shares in the company, valued at $103,348,217.52. This trade represents a 11.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO William John Sibold sold 2,400 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $575.34, for a total value of $1,380,816.00. Following the transaction, the chief executive officer owned 150,074 shares in the company, valued at approximately $86,343,575.16. This represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 99,537 shares of company stock valued at $53,485,702 over the last 90 days. 21.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

MDGL has been the topic of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Monday, January 12th. Cantor Fitzgerald raised shares of Madrigal Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Tuesday, November 4th. Canaccord Genuity Group increased their price objective on shares of Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. B. Riley Financial boosted their target price on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Citizens Jmp increased their price target on shares of Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the company a “market outperform” rating in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $663.86.

Madrigal Pharmaceuticals Trading Down 11.1%

NASDAQ MDGL opened at $436.87 on Friday. The stock has a market cap of $9.92 billion, a PE ratio of -33.58, a PEG ratio of 6.98 and a beta of -1.01. Madrigal Pharmaceuticals, Inc. has a 12 month low of $265.00 and a 12 month high of $615.00. The company’s 50-day moving average price is $524.34 and its 200-day moving average price is $480.46. The company has a current ratio of 3.44, a quick ratio of 3.26 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($2.61). The company had revenue of $321.08 million during the quarter, compared to analysts’ expectations of $310.36 million. Madrigal Pharmaceuticals had a negative net margin of 39.04% and a negative return on equity of 41.50%. During the same period last year, the firm earned ($2.71) earnings per share. Madrigal Pharmaceuticals’s quarterly revenue was up 210.8% on a year-over-year basis. Equities research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.